A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
A FITC-induced allergic contact hypersensitivity model was used to investigate the role that the prostaglandin D(2) receptor-chemoattractant receptor-homologous molecule expressed on T(h)2 cells (CRTH2) plays in modulating cutaneous inflammation. Our results show that inhibition of CRTH2, achieved via administration of a potent, small molecule antagonist, Compound A (Cmpd A), effectively blocked edema formation and greatly reduced the inflammatory infiltrate and skin pathology observed in drug vehicle-treated animals. Gene expression analysis revealed that Cmpd A administration down-regulated the transcription of a wide range of pro-inflammatory mediators. This correlated with decreases in cytokine and chemokine protein levels, notably IL-4, IL-1beta, tumor necrosis factor-alpha, transforming growth factor-beta, GRO-alpha, MIP-2 and thymic stromal lymphopoietin (TSLP) in FITC-challenged ears. The administration of an anti-TSLP-neutralizing antibody was only partially effective in lowering the FITC-induced inflammatory infiltrate and cytokine production compared with the CRTH2 antagonist. Taken together, these data suggest that blockade of CRTH2 inhibits multiple pathways leading to cutaneous inflammation in this model. This suggests that CRTH2 antagonism may be a viable route for therapeutic intervention in allergic skin diseases, such as atopic dermatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as shown in vitro and in animal models154,155, has an important role in TH2-mediated inflammation of AD by directing their migration into the skin.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [154]
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.255 · Cited by 1,099
Allakhverdi, Z., Comeau, M. R., Jessup, H. K., Yoon, B.-R. P., Brewer, A., Chartier, S., Paquette, N., Ziegler, S. F., Sarfati, M., & Delespesse, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062211 · Cited by 786 · cited 1×
“TSLP is expressed by epithelial cells, including keratinocytes, and its expression is induced by a wide range of stimuli including IL-1b and certain tolllike receptor ligands ( 7 ).”
BackgroundDifferential in situ cytokine gene expression in acute versus chronic atopic dermatitis.
Hamid, Q., Boguniewicz, M., & Leung, D. Y. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117408 · Cited by 778 · cited 1×
“control patients (4) and an increased expression of Th2 cytokines, including IL-4, IL-5, IL-13 and tumor necrosis factor-a (TNF-a) ( 5 ).”
BackgroundLiu, Y.-J., Soumelis, V., Watanabe, N., Ito, T., Wang, Y.-H., de Waal Malefyt, R., Omori, M., Zhou, B., & Ziegler, S. F. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141718 · Cited by 659 · cited 2×
“ability of dibutyl phthalate to act as an adjuvant may in part be attributable to our observation of its ability to induce TSLP production, thereby activating the skin dendritic cells ( 6 ) and Langerhans cells (33).”
BackgroundYoo, J., Omori, M., Gyarmati, D., Zhou, B., Aye, T., Brewer, A., Comeau, M. R., Campbell, D. J., & Ziegler, S. F. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041503 · Cited by 613 · cited 1×
“Transgenic mice engineered to over-express TSLP in keratinocytes develop an AD-like phenotype, including eczematous lesions containing inflammatory dermal infiltrates and elevated serum IgE levels ( 8 ).”
BackgroundThymic stromal lymphopoietin: master switch for allergic inflammation
Liu, Y.-J. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051745 · Cited by 576 · cited 2×
“We examined the production of TSLP because (i) it is over-expressed in AD lesions ( 29 ), (ii) has the ability to elicit IL-4 production from murine CD4+ T lymphocytes (30, 31) and (iii) can prime skin-residing dendritic cells for activation and migration to draining lymph nodes upon antigen capture (4).”
BackgroundBiedermann, T., Kneilling, M., Mailhammer, R., Maier, K., Sander, C. A., Kollias, G., Kunkel, S. L., Hültner, L., & Röcken, M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.10.1441 · Cited by 395
The immunogenetics of asthma and eczema: a new focus on the epithelium
Cookson, W. (2004) · Nature Reviews Immunology · doi:10.1038/nri1500 · Cited by 389 · cited 1×
“A number of genes that have been genetically linked to atopic diseases are also up-regulated by FITC treatment and have decreased expression upon Cmpd A treatment ( 25 ).”
Background
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Woodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
Mast cells in atopic dermatitis
Kawakami, T., Ando, T., Kimura, M., Wilson, B. S., & Kawakami, Y. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.09.006 · Cited by 362
“Administration of a CRTH2 antagonist, compound A, ameliorated skin inflammation caused by either EC OVA or FITC sensitization [92,93].”
BackgroundOyoshi, M. K., Larson, R. P., Ziegler, S. F., & Geha, R. S. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.041 · Cited by 304
The Biology of Thymic Stromal Lymphopoietin (TSLP)
Ziegler, S. F., Roan, F., Bell, B. D., Stoklasek, T. A., Kitajima, M., & Han, H. (2013) · Advances in Pharmacology · doi:10.1016/b978-0-12-404717-4.00004-4 · Cited by 298
“…isothiocyanate (FITC)-mediated contact hypersensitivity (CHS), since ear swelling was minimal if blockade of TSLP occurred prior to sensitization, but was only modestly reduced when TSLP blockade occurred after sensitization but prior to challenge (Boehme et al., 2009; Larson et al., 2010).”
Metadata
- Authors
- Boehme, S. A., Franz-Bacon, K., Chen, E. P., Sasik, R., Sprague, L. J., Ly, T. W., Hardiman, G., & Bacon, K. B.
- Affiliations
- University of California San Diego (US)
- University of California System (US)
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-09
- Volume
- 21
- Issue
- 1
- Pages
- 81-93
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- PMC
- PMC2638841
- OpenAlex
- W2104712354
- Cited by
- 60
- References
- 35
- Citations by year
- 2024: 5 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 3 · 2017: 5 · 2016: 4 · 2014: 2 · 2013: 6 · 2012: 7
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- International Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK063491)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- CRTH2, prostaglandin D2 receptor, small molecule antagonists, compound A, contact allergy, skin inflammation, thymic stromal lymphopoietin, cytokines, chemokines, IL-4, atopic dermatitis, anti-inflammatory therapy
- MeSH terms
- Animals, Cell Line, Female, Humans, Mice, Inbred BALB C, Prostaglandin Antagonists, Receptors, Immunologic, Receptors, Prostaglandin, Prostaglandin D2, Gene Expression, Cytokines, Fluorescein-5-isothiocyanate, Dermatitis, Allergic Contact, Th2 Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. https://app.cochat.ai/papers/10.1093/intimm/dxn127
- The paper
- Boehme, S. A., Franz-Bacon, K., Chen, E. P., Sasik, R., Sprague, L. J., Ly, T. W., Hardiman, G., & Bacon, K. B. (2009). A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. International Immunology. https://doi.org/10.1093/intimm/dxn127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.